EICHORPublic-registry site landscape for NCT06276556, “Extension Study of ABP-671 in Participants With Gout”, a Gout study sponsored by Atom Therapeutics Co., Ltd. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06276556 (registry record) |
| Study title | Extension Study of ABP-671 in Participants With Gout |
| Official title | A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301 |
| Sponsor | Atom Therapeutics Co., Ltd |
| Condition(s) | Gout |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 54 |
| Site countries | United States, Australia, Georgia, Guatemala, Taiwan |
Patient-friendly overview of this study: eichor.com/study/NCT06276556.
Eichor generates a preliminary site-risk snapshot for NCT06276556 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Gout trials
← Eichor home · All tracked trials · Gout studies · Weekly briefs
